Prognostic and Clinicopathological Significance of CXCL1 Expression in Gastric Cancer: A Meta-Analysis.

Abstract Background: Some studies have shown that CXCL1 expression in gastric cancer (GC) is associated with survival and clinicopathological characteristics. However, the evidence remains inconclusive. Thus, we aim to further explore the clinicopathological significance and potential prognostic role of CXCL1 expression in GC.Methods: Databases of EMBASE, PubMed Web of Science and the Cochrane Library were systematically searched for the eligible studies from their establishment to July 16, 2020, which reported the association between CXCL1 expression and survival in GC. The quantitative meta-analysis was carried out with Stata SE12.0 software. Results: A total of 1474 patients from 9 eligible studies were included in the present meta-analysis. Our results demonstrated that elevated expression level of CXCL1 was significantly associated with poor overall survival (OS) (HR=1.68; 95%CI: 1.26-2.24, P<0.001). The subgroup analysis revealed that elevated CXCL1 expression was found to be associated with a poor OS in Chinese and Japanese patients. Moreover, the stratification analysis by detection methods showed that elevated CXCL1 expression had a significantly poor OS effect on GC patients by IHC but not by RT-PCR. Besides, high CXCL1 expression was obviously associated with higher depth of tumor invasion, earlier lymph node metastasis and more advanced TNM stage compared with low CXCL1 expression in GC.Conclusions: CXCL1 may serve as a potential biomarker to predict prognosis and clinicopathological features in GC.

Download Full-text

Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

10.21203/rs.3.rs-20428/v3 ◽

2020 ◽

Author(s):

Yiding Li ◽

Guiling Wu ◽

Wanli Yang ◽

Xiaoqian Wang ◽

Lili Duan ◽

...

Keyword(s):

Therapeutic Response ◽

Meta Analysis ◽

Prognostic Significance ◽

Pooled Analysis ◽

Clinicopathological Characteristics ◽

Cochrane Library ◽

Cellsearch System ◽

Poor Overall Survival ◽

Response To Chemotherapy ◽

The Cochrane Library

Abstract Background: Esophageal carcinoma (EC) is the seventh-most prevalent tumor in the world, which is still one of the primary causes of tumor-related death. Identifying noteworthy biomarkers for EC is particularly significant in guiding effective treatment. Recently, circulating tumor cells (CTCs) in peripheral blood (PB) were intensively discussed as prognostic markers in patients with EC. However, an ongoing controversy still exists regarding the prognostic significance of CTCs determined by the CellSearch system in EC sufferers. This meta-analysis was designed to approach this topic. Methods: We systematically conducted searches using PubMed, Medline, Web of Science and the Cochrane Library for relevant studies, which were published through February 20, 2020. Using the random-effects model, our study was performed in Review Manager software, with odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence intervals (CIs) as the effect values. Results: Totally 7 articles were finally included in this study. For clinicopathological characteristics, the pooled results on TNM stage indicated that the III/IV group had higher rate of CTCs compared with the I/II group (OR=1.36, 95% CI: 0.68-2.71, I2=0%). Incidence of CTCs was higher in patients with T3/T4 stage (OR=2.92, 95% CI: 1.31-6.51, I2=0%) and distant metastasis group (OR=5.18, 95% CI: 2.38-11.25, I2=0%) compared to patients with T1/T2 stage or non-metastatic group. The pooled analysis revealed that CTC positivity detected in EC patients was correlated with poor overall survival (OS) (HR=2.83, 95% CI:1.99-4.03, I2=0%) and relapse-free survival (RFS) (HR=4.71, 95% CI:2.73-8.13, I2=0%). When pooling the estimated RR, a poor therapeutic response to chemoradiotherapy was discovered in patients with CTC positivity (RR=1.99, 95% CI:1.73-2.29, I2=60%). Conclusions: In summary, our meta-analysis demonstrated that CTCs positivity determined by the CellSearch system are correlated with the prognosis of EC patients and might indicate a poor therapeutic response to chemotherapy in EC patients.

Download Full-text

Association between aberrant APC promoter methylation and breast cancer pathogenesis: a meta-analysis of 35 observational studies

PeerJ ◽

10.7717/peerj.2203 ◽

2016 ◽

Vol 4 ◽

pp. e2203 ◽

Cited By ~ 5

Author(s):

Dan Zhou ◽

Weiwei Tang ◽

Wenyi Wang ◽

Xiaoyan Pan ◽

Han-Xiang An ◽

...

Keyword(s):

Breast Cancer ◽

Observational Studies ◽

Meta Analysis ◽

Random Effect ◽

Random Effect Model ◽

Wnt Signaling Pathway ◽

Detection Methods ◽

Cochrane Library ◽

Cancer Pathogenesis ◽

Potential Biomarker

Background.Adenomatous polyposis coli (APC) is widely known as an antagonist of the Wnt signaling pathway via the inactivation ofβ-catenin. An increasing number of studies have reported that APC methylation contributes to the predisposition to breast cancer (BC). However, recent studies have yielded conflicting results.Methods.Herein, we systematically carried out a meta-analysis to assess the correlation between APC methylation and BC risk. Based on searches of the Cochrane Library, PubMed, Web of Science and Embase databases, the odds ratio (OR) with 95% confidence interval (CI) values were pooled and summarized.Results.A total of 31 articles involving 35 observational studies with 2,483 cases and 1,218 controls met the inclusion criteria. The results demonstrated that the frequency of APC methylation was significantly higher in BC cases than controls under a random effect model (OR= 8.92, 95% CI [5.12–15.52]). Subgroup analysis further confirmed the reliable results, regardless of the sample types detected, methylation detection methods applied and different regions included. Interestingly, our results also showed that the frequency of APC methylation was significantly lower in early-stage BC patients than late-stage ones (OR= 0.62, 95% CI [0.42–0.93]).Conclusion.APC methylation might play an indispensable role in the pathogenesis of BC and could be regarded as a potential biomarker for the diagnosis of BC.

Download Full-text

LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis

Bioscience Reports ◽

10.1042/bsr20193532 ◽

2020 ◽

Vol 40 (8) ◽

Author(s):

Shubo Tian ◽

Jinglei Liu ◽

Shuai Kong ◽

Lipan Peng

Keyword(s):

Survival Data ◽

Poor Prognosis ◽

Meta Analysis ◽

Tumor Stage ◽

Clinicopathological Characteristics ◽

Clinicopathological Features ◽

High Expression ◽

Cochrane Library ◽

Poor Overall Survival ◽

The Cochrane Library

Abstract Objective: Recent studies have shown that distal-less homeobox 6 antisense 1 (DLX6-AS1) is aberrantly expressed in various cancers and is associated with poor prognosis. This meta-analysis is designed to investigate the effects of DLX6-AS1 expression on clinicopathological features and survival outcomes. Methods: All eligible studies were searched from Pubmed, Web of Science, Embase, the Cochrane Library, and Wanfang database, up to August 2019. The literature was selected according to the inclusion and exclusion criteria listed in this work, and the quality of each eligible study was assessed. Each patient’s clinicopathological features and survival data were analyzed using Stata12.0 software. Begg’s test and sensitivity analysis were also conducted. Results: A total of 12 articles were included, covering 841 patients. Results showed that high expression of DLX6-AS1 was significantly closely associated with poor overall survival in tumor patients (hazard ratio (HR) = 2.30, confidence interval (95% CI): 1.70–3.09, P<0.01). This meta-analysis also showed that overexpression of DLX6-AS1 was significantly associated with tumor stage (P<0.01), tumor size (P<0.01), lymph node metastasis (P<0.01), and distant metastasis (P<0.01). Begg’s test suggested no publication bias. Conclusion: This meta-analysis revealed that high expression of DLX6-AS1 was related to the advanced clinicopathological characteristics of human digestive system cancers (gastric cancer, esophageal cancer, colon cancer, pancreatic cancer, and hepatocellular carcinoma) and other cancers such as ovarian cancer, osteosarcoma and non-small cell lung cancer, and DLX6-AS1 has important predictive value for poor prognosis. However, more studies are needed to further corroborate these findings.

Download Full-text

Clinicopathological significance and prognosis of long noncoding RNA SNHG14 expression in human cancers: A Meta-Analysis and bioinformatics analysis

10.21203/rs.3.rs-1209386/v1 ◽

2021 ◽

Author(s):

Bin Liu ◽

Tingting Lu ◽

Yongfeng Wang ◽

Yaqiong Chen ◽

Shixun Ma ◽

...

Keyword(s):

Noncoding Rna ◽

Cox Regression ◽

Meta Analysis ◽

Prognostic Significance ◽

Clinicopathological Characteristics ◽

The Cancer Genome Atlas ◽

Cochrane Library ◽

Poor Overall Survival ◽

Significant Difference ◽

Pan Cancer

Abstract Background SNGH14 is a recently found long non-coding RNA (lncRNA) with a strong link to cancer. However, it is uncertain if the expression of SNHG14 is linked to the prognosis of individuals with various forms of cancer. We conducted a meta-analysis of the available literature to evaluate the association between SNHG14 and clinicopathological characteristics and patient prognosis Methods The databases PubMed/Medline, Web of Science, Cochrane Library, and Embase were combed for relevant papers published till November 2021. The odds ratio (OR) and 95% confidence interval (CI) were used to analyze dichotomous variables, while the hazard ratio (HR) and 95% CI were employed as a summary statistic for survival outcomes. In addition, the Cancer Genome Atlas TCGA (TCGA) and gene expression omnibus (GEO) database were utilized to investigate SNHG14 differential expression in pan-cancers. Cox regression and Kaplan-Meier analysis were used to investigate the prognostic significance of SNHG14 in pan-cancer. The association between the degree of SNHG14 expression in pan-cancer and immune infiltration, tumor mutational burden (TMB), and microsatellite instability (MSI) was measured using Spearman correlations. Results A total of 21 studies with 1,080 patients, mainly from China, were included. Our results showed that elevated SNHG14 expression was significantly associated with poor overall survival (OS) (HR = 1.39; 95% CI: 1.06-1.83; P = 0.017). In addition, increased SNHG14 expression was associated with tumor size (OR = 1.60; 95% CI: 1.20-2.14; P = 0.001), TNM staging (OR = 0.54; 95% CI: 0.40-0.71; P <0.001), lymph node metastasis (OR = 1.86; 95% CI: 1.35-2.55; P <0.001), differentiation grade (OR = 1.95; 95% CI: 1.36-2.80; P <0.001), and distant metastasis (OR = 2.44; 95% CI: 1.30 -4.58; P= 0.005). However, there was no significant difference in age (OR = 1.02; 95% CI: 0.77-1.33; P = 0.863) and gender (OR = 0.98; 95% CI: 0.72-1.35; P = 0.915). Conclusion This study revealed that overexpression of SNGH14 is associated with low OS rate and clinicopathological characteristics. SNGH14 can be considered as a new tumor marker that aids in early tumor diagnosis, thus improving the prognosis of patients.

Download Full-text

The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis

Technology in Cancer Research & Treatment ◽

10.1177/15330338211043784 ◽

2021 ◽

Vol 20 ◽

pp. 153303382110437

Author(s):

Yuanyuan Lu ◽

Li Li

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Meta Analysis ◽

Circulating Tumor Dna ◽

Detection Methods ◽

Source Analysis ◽

Cochrane Library ◽

Potential Biomarker ◽

Effect Ratio ◽

Tumor Dna

Background: Studies have shown that circulating tumor DNA (ctDNA) indicates a poor prognosis in ovarian cancer. In this study, meta-analysis was used to assess the relationship between ctDNA and the prognosis of patients with epithelial ovarian cancer. Methods: The clinical trials included in this study were obtained via a search of PubMed, the Cochrane Library, the Web of Science and Embase between the period of establishment and March 2020. We selected clinical studies using qualitative or quantitative ctDNA methods to analyse the prognosis of ovarian epithelial cancer, screened the studies according to the determined inclusion and exclusion criteria, and used the modified JADAD score scale and NOS scale for evaluation, with OS (overall survival) and PFS (progression-free survival) as end events. The Cochrane Evaluation Tool was used to evaluate the quality of the randomized controlled trials. Stata 15.0 software was used to combine the effect ratio (hazard ratio, HR) and its 95% confidence interval (CI). In addition, a source analysis of ctDNA specimens, an analysis of ctDNA detection methods and a subgroup and sensitivity analysis of FIGO staging were performed. Results: A total of 8 studies were included in this meta-analysis, and ctDNA was found to be an independent risk factor for patients with epithelial ovarian cancer (OS: HR = 2.36, 95% CI [1.76,3.17], P < .001; PFS: HR = 2.51, 95% CI [1.83,3.45]). Conclusions: The results of our analysis suggested that ctDNA is a potential biomarker that can be used to evaluate the prognosis of patients with ovarian cancer.

Download Full-text

Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis

10.21203/rs.2.21100/v1 ◽

2020 ◽

Author(s):

Ruonan Jiao ◽

Wei Jiang ◽

Xin Wei ◽

Mengpei Zhang ◽

Si Zhao ◽

...

Keyword(s):

Noncoding Rna ◽

Smoking Status ◽

Histological Grade ◽

Meta Analysis ◽

Prognostic Significance ◽

Cochrane Library ◽

Human Cancers ◽

Potential Association ◽

Elevated Expression ◽

Clinicopathological Significance

Abstract Background Recent studies have highlighted the important role of long non-coding RNA SNHG16 in various human cancers. Here, we conducted a meta-analysis to investigate the effect of SNHG16 expression on clinicopathological features and prognosis in patients with different kinds of human cancers.Methods We performed a systematic search in electronic databases including PubMed, EMBASE, Cochrane Library and Web of Science, to investigate the potential association between SNHG16 expression and prognostic significance and clinical features in cancer patients. Odds ratios (ORs) or hazards ratios (HRs) with corresponding 95% confidence intervals (95% CIs) were pooled to estimate the prognosis value of SNHG16 by StataSE 15.0 software.Results A total of 16 eligible studies with 1299 patients were enrolled in our meta-analysis. The results revealed that increased expression level of SNHG16 was significantly associated with larger tumor size (OR: 3.357; 95% CI: 2.173-5.185; P < 0.001), advanced TNM stage (OR: 2.930; 95% CI: 1.522-5.640; P = 0.001) and poor histological grade (OR: 3.943; 95% CI: 1.955-7.952; P < 0.001), but not correlated with smoking status (P = 0.489), sex (P = 0.932), distant metastasis (P = 0.052), or lymph node metastasis (P = 0.155). Moreover, the pooled HR showed that elevated expression SNHG16 was associated with a significantly poorer overall survival (OS) (HR=1.866, 95% CI: 1.571-2.216, P <0.001).Conclusions LncRNA SNHG16 overexpression might serve as a convinced unfavorable prognostic factor, which provides a basis for medical workers to evaluate the prognosis of patients and to help the decision-making process.

Download Full-text

LncRNA SNHG7 serves as a potential biomarker on prognosis of human solid tumors: a meta-analysis

Current Pharmaceutical Biotechnology ◽

10.2174/1389201022666210104121207 ◽

2021 ◽

Vol 22 ◽

Author(s):

Ping Yi ◽

Wenchao Zhang ◽

Ming Yang ◽

Qianjin Lu ◽

Haijing Wu

Keyword(s):

Predictive Value ◽

Meta Analysis ◽

Human Tumor ◽

Tumor Location ◽

Cochrane Library ◽

Tumor Biomarker ◽

Solid Cancer ◽

Poor Overall Survival ◽

Potential Biomarker ◽

And Gender

Background and Objective: Emerging studies upon the predictive value of small nucleolar RNA host gene 7 (SNHG7) in human neoplasms give evidence of the association of SNHG7 with human tumor. However, whether SNHG7 can be utilized as a biomarker for carcinoma is still unknown. Therefore, this meta-analysis is aimed to assess the possibility of SNHG7 serving as a tumor biomarker. Material and Methods: 11 studies involving 814 cancer patients was retrieved from several databases, including Pubmed, Embase, the Cochrane Library, and Web of Science from 1950 to Dec 27, 2019. Data of patient survival and several clinicopathological features were extracted and analyzed. Results: Evident association between SNHG7 expression and poor overall survival (OS) was demonstrated (HR=1.84, 95% CI: 1.42-2.37) and high SNHG7 level was markedly correlated with tumor size (OR=2.01, 95% CI: 1.27-3.19), advanced clinical grade (III/IV) (OR=3.90, 95% CI: 2.63-5.80), lymphatic metastasis (LM) (OR=4.53, 95% CI: 2.71-7.55) and distant metastasis (DM) (OR=3.52, 95% CI: 2.58-4.80), except from age and gender. Subgroup analysis showed that the predictive value of SNHG7 was consistent regardless of follow-up months, tumor location and sample size. Additionally, data from R2 database also confirmed this association (p < 0.05). Publication bias was evaluated using Begg’s and Egger’s test. Conclusion: SNHG7 could serve for a promising biomarker to predict prognosis, progression and metastasis of human solid cancer.

Download Full-text

Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis

Bioscience Reports ◽

10.1042/bsr20203995 ◽

2021 ◽

Author(s):

Weiwei Chen ◽

Yuting Li ◽

Liliangzi Guo ◽

Chenxing Zhang ◽

Shaohui Tang

Keyword(s):

Meta Analysis ◽

Clinical Stage ◽

Predictive Marker ◽

Clinicopathological Characteristics ◽

Cochrane Library ◽

Hazard Ratios ◽

Non Coding Rna ◽

The Relationship ◽

Long Non Coding Rna

Background: Several studies have assessed the relationship between long non-coding RNA five prime to Xist (FTX) expression, clinicopathological features, and survival outcomes in cancer patients with conflicting results. This meta-analysis synthesized existing data to clarify the association between FTX with cancer prognosis.Methods: PubMed, Embase, Cochrane library, Web of Science, Chinese CNKI, and the Chinese WanFang databases were used to search for relevant studies. Role of FTX in cancers was evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs).Results: Eleven studies comprising 1,210 participants including colorectal cancer (CRC), hepatocellular carcinoma (HCC), gastric cancer (GC), renal cell carcinoma (RCC), osteosarcoma (OSC), and glioma were enrolled in this analysis. The meta-analysis showed that high FTX expression was significantly associated with several clinicopathological characteristics, including lymph node metastasis in patients with CRC, GC, HCC, and RCC, distant metastasis in patients with CRC, GC, HCC, and OSC, larger tumor size in patients with CRC, GC, HCC, RCC, and OSC, and subsequently TNM/clinical stage in patients with CRC, GC, HCC, OSC, and glioma. The pooled results from the survival analysis revealed a significant correlation between high FTX expression and shorter OS in patients with HCC, CRC, GC, OSC, and glioma. Further, FTX overexpression could be an independent predictive marker for shorter OS in patients with CRC, HCC, OSC, and glioma. Conclusions: FTX may be a potential oncogene, with high FTX expression being associated with a poorer prognosis in patients with CRC, HCC, OSC, and glioma

Download Full-text

WNT5A Correlates with Clinicopathological Characteristics in Gastric Cancer: a Meta-Analysis

Cellular Physiology and Biochemistry ◽

10.1159/000455934 ◽

2017 ◽

Vol 41 (1) ◽

pp. 33-40 ◽

Cited By ~ 8

Author(s):

Seungyoon Nam ◽

Jun-Won Chung ◽

Jun-Young Yang

Keyword(s):

Gastric Cancer ◽

Wnt Signaling ◽

Meta Analysis ◽

Clinicopathological Characteristics ◽

Cochrane Library ◽

Systematic Analysis ◽

Advanced Tumor ◽

Advanced Stages ◽

Cancer Types ◽

Embryonic Signaling

Background/Aims: Gastric cancer (GC), the third-leading cause of cancer death in the world, is typically diagnosed only in its advanced stages. WNT signaling has been associated with clinicopathological characteristics in diverse cancer types. But the systematic analysis of WNT5A, a member in the signaling, has not been inspected. Thus, our study used a meta-analysis to statistically associate WNT5A expression with GC clinicopathological characteristics. Methods: For a systematic literature review of GC in combination with the WNT signaling molecule WNT5A, we searched for PubMed, Cochrane Library, and Web of Science. It led to the five cohorts, in four eligible studies, consisting of 1,034 patients (617 WNT5A-positive and 417 WNT5A-negative patients). These patients were inspected by the library “meta” in R software for our meta-analysis. Results: Our meta-analysis, revealed a statistically significant associations of WNT5A-positivity with lymph node metastasis (p=0.0047), some types of Lauren diffuse subtype GCs (p<0.0001), advanced tumor depth (p<0.0001), and advanced UICC stages (p=0.0461) with no observation of bias or confounding factors. Conclusions: These results support the feasibility of targeting this embryonic signaling pathway, both for therapy, and as a biomarker to “guide” various individual interventions (i.e., “personalized medicine”).

Download Full-text

Systematic Review and Meta-Analysis of the Utility of Circular RNAs as Biomarkers of Hepatocellular Carcinoma

Canadian Journal of Gastroenterology and Hepatology ◽

10.1155/2019/1684039 ◽

2019 ◽

Vol 2019 ◽

pp. 1-13 ◽

Cited By ~ 2

Author(s):

Qingqin Hao ◽

Yadi Han ◽

Wei Xia ◽

Qinghui Wang ◽

Huizhong Qian

Keyword(s):

Likelihood Ratio ◽

Meta Analysis ◽

Positive Likelihood Ratio ◽

Negative Likelihood Ratio ◽

Diagnostic Odds Ratio ◽

Clinicopathological Characteristics ◽

Cochrane Library ◽

Circular Rnas ◽

Clinical Value ◽

Sensitivity Specificity

Emerging studies have reported circRNAs were dysregulated in HCC. However, the clinical value of these circRNAs remains to be clarified. Herein, we aimed to comprehensively explore their association with the diagnosis, prognosis, and clinicopathological characteristics of HCC. PubMed, EMBASE, Web of Science, and Cochrane Library databases were comprehensively searched for eligible studies up to October 30, 2018. The diagnostic effect was evaluated by the pooled sensitivity, specificity, and other indexes. The pooled hazard ratio (HR) for overall survival (OS) and recurrence free survival (RFS) was calculated to assess the prognostic value. Ten studies on diagnosis, 12 on prognosis, and 23 on clinicopathology were identified from the databases. A total of 11 upregulated and 11 downregulated circRNAs showed an association with clinicopathological features of HCC. For the diagnosis analyses, the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) of circRNAs for HCC were 0.74 (95%CI: 0.65-0.82) and 0.76 (95%CI: 0.70-0.81), 3.1 (95%CI: 2.5-3.8), 0.34 (95%CI: 0.25-0.47), and 9 (95%CI: 6-14), respectively. The area under SROC curve (AUC) was 0.81 (95% CI: 0.78–0.84), indicating moderate diagnostic accuracy. In stratified analyses, the diagnostic performance of circRNAs varied based on the source of control and specimen type. For the prognosis analyses, increased expression of upregulated circRNAs was associated with worse OS (HR: 3.67, 95%: 2.07-6.48), while high expression of downregulated circRNAs was associated with better OS (HR: 0.38, 95%: 0.30-0.48). In conclusion, this study reveals that circRNAs may serve as promising diagnostic and prognostic biomarkers for HCC. However, further investigations are still required to explore the clinical value of circRNAs.

Download Full-text